期刊
MOLECULAR CANCER THERAPEUTICS
卷 8, 期 1, 页码 1-9出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-08-0801
关键词
-
类别
资金
- NIH [CA52995, CA 17094, CA95060, CA610159]
- NATIONAL CANCER INSTITUTE [R01CA061015, U19CA052995, U01CA052995, P01CA017094, P50CA095060] Funding Source: NIH RePORTER
The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is currently one of the most exciting drug targets in oncology. However, only a short time ago, the paradigm existed that drugs targeted to the four PI3K class I isoforms would be too toxic for use in cancer therapy due to effects on physiologic signaling. Since that time, studies have delineated the roles of these four isoforms in nonpathologic signaling as well as their roles in cancer. An extensive effort has gone Into developing agents that inhibit one or more PI3K isoforms, as well as closely related proteins implicated in cancer. These agents have proved to be tolerable and therapeutically beneficial in animal studies, and a number are in clinical testing. The agents, their properties, and their molecular targets are discussed in this review. [Mol Cancer Ther 2009;80):1 - 9]
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据